Cargando…

Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Pharmacokinetic-pharmacodynamic (PKPD) models have met increasing interest as tools to identify potential efficacious antibiotic dosing regimens in vitro and in vivo. We sought to investigate the impact of diversely shaped clinical pharmacokinetic profiles of meropenem on the growth/killing patterns...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minichmayr, Iris K., Kappetein, Suzanne, Brill, Margreke J. E., Friberg, Lena E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404958/ https://www.ncbi.nlm.nih.gov/pubmed/36009905 http://dx.doi.org/10.3390/antibiotics11081036

Ejemplares similares

Meropenem: continuous or extended infusion?
por: Frippiat, Frédéric, et al.
Publicado: (2020)

Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis
por: Yu, Zhenwei, et al.
Publicado: (2018)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
por: Moore, Sarah E, et al.
Publicado: (2019)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
por: Lorente, L, et al.
Publicado: (2005)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
por: Dahdouh, E., et al.
Publicado: (2014)

Comparison of the Effectiveness of Prolonged Infusion and Intermittent Infusion of Meropenem in Patients With Sepsis: A Meta-Analysis
por: Lokhandwala, Adnan, et al.
Publicado: (2023)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
por: Manning, Laurens, et al.
Publicado: (2014)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
por: Hassuna, Noha Anwar, et al.
Publicado: (2020)

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

Therapeutic drug monitoring of meropenem and piperacilin administered in continuous infusion. preliminary data
por: Miralbés Torner, M, et al.
Publicado: (2015)

Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm
por: Alam, Farhana, et al.
Publicado: (2020)

Transcriptional profiling of Pseudomonas aeruginosa mature single- and dual-species biofilms in response to meropenem
por: Alam, Farhana, et al.
Publicado: (2023)

Effect of combined colistin and meropenem against meropenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa by checkerboard method: A cross sectional analytical study
por: Gunalan, Anitha, et al.
Publicado: (2021)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

First Report of bla(OXA-677) with Enhanced Meropenem-Hydrolyzing Ability in Pseudomonas aeruginosa in China
por: Sun, Yue, et al.
Publicado: (2021)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa
por: Cojutti, Pier Giorgio, et al.
Publicado: (2020)

An investigation of the stability of meropenem in elastomeric infusion devices
por: Foy, Finbarr, et al.
Publicado: (2019)

Continuous infusion versus intermittent administration of meropenem in critically ill patients: a pilot study
por: Thalhammer, F, et al.
Publicado: (1999)

Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
por: Tiede, Christoph, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa
por: Felton, T. W., et al.
Publicado: (2013)

In Vivo Development of Aztreonam Resistance in Meropenem-Resistant Pseudomonas aeruginosa Owing to Overexpression of the bla(PDC-16)
por: Ding, Li, et al.
Publicado: (2023)

Successful treatment of multidrug-resistant Pseudomonas aeruginosa keratitis with meropenem eye drops — a case report
por: Elhardt, Carolin, et al.
Publicado: (2023)

Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report
por: Conde-Díaz, Cristina, et al.
Publicado: (2017)

Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion
por: Venugopalan, Veena, et al.
Publicado: (2018)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis
por: Álvarez Otero, Judith, et al.
Publicado: (2020)

Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

The Anti-Pseudomonas aeruginosa Antibody Panobacumab Is Efficacious on Acute Pneumonia in Neutropenic Mice and Has Additive Effects with Meropenem
por: Secher, Thomas, et al.
Publicado: (2013)

1597. Ceftolozane-Tazobactam and Meropenem Synergy Testing Against Multi-Drug and Extensively-Drug Resistant Pseudomonas aeruginosa
por: Chua, Mary Francine P, et al.
Publicado: (2020)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation
por: Castanheira, Mariana, et al.
Publicado: (2023)

Case report: Successful experience using continuous infusion of meropenem in a geriatric patient with hip fracture complicated by sepsis
por: Kadralinova, Assiya, et al.
Publicado: (2023)

61. Short- versus prolonged-courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection
por: Bae, Moonsuk, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5nt10qoe7icoiflgfio8tc72e3